Get the Stockscreener App
0.63
5.12%
0.0307
Salarius Pharmaceuticals Inc stock is traded at $0.63, with a volume of 4.04M.
It is up +5.12% in the last 24 hours and down -28.19% over the past month.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
See More
Previous Close:
$0.5993
Open:
$0.6683
24h Volume:
4.04M
Relative Volume:
1.49
Market Cap:
$1.34M
Revenue:
$4.70M
Net Income/Loss:
$-4.99M
P/E Ratio:
-0.0981
EPS:
-6.42
Net Cash Flow:
$-5.29M
1W Performance:
-16.00%
1M Performance:
-28.19%
6M Performance:
-71.88%
1Y Performance:
-74.29%
1-Day Range:
$0.5876
$0.70
1-Week Range:
$0.5876
$2.31
52-Week Range:
$0.4519
$7.20
Salarius Pharmaceuticals Inc Stock (SLRX) Company Profile
Name
Salarius Pharmaceuticals Inc
Sector
Industry
Phone
346-772-0346
Address
2450 HOLCOMBE BLVD, HOUSTON
Compare SLRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLRX
Salarius Pharmaceuticals Inc
|
0.63 | 1.27M | 4.70M | -4.99M | -5.29M | -6.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Salarius Pharmaceuticals Inc Stock (SLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-20 | Initiated | Ladenburg Thalmann | Buy |
Salarius Pharmaceuticals Inc Stock (SLRX) Latest News
Salarius Pharmaceuticals Inc. Company’s Quarterly Earnings Growth: What the Numbers SayFree Watchlist for Low Risk High Return - Newser
Relative strength of Salarius Pharmaceuticals Inc. in sector analysisDaily Trade Monitor with Pattern Alerts - Newser
Signal strength of Salarius Pharmaceuticals Inc. stock in tech scannersWeekly Portfolio Update with ROI Focus - Newser
Volatility clustering patterns for Salarius Pharmaceuticals Inc.Short-Term AI-Based Stock Price Forecast - Newser
Will Salarius Pharmaceuticals Inc. bounce back from current supportFree Smart Money Tracking Signal Generator - Newser
Published on: 2025-07-31 23:35:14 - Newser
How Interest Rate Changes Impact Salarius Pharmaceuticals Inc. Stock PerformanceFree Real Time Stock Movement Analysis - Newser
What analysts say about Salarius Pharmaceuticals Inc. stock outlookSwing Trade Picks with High Potential - Newser
Is Salarius Pharmaceuticals Inc. stock overvalued or undervaluedEarnings Report Outlook For 2025 - jammulinksnews.com
Regression analysis insights on Salarius Pharmaceuticals Inc. performanceFree Low Risk High Return Opportunities - Newser
How does Salarius Pharmaceuticals Inc. compare to its industry peersPost Market Alerts For Every Investor - jammulinksnews.com
Salarius Pharmaceuticals Modifies Security Holders’ Rights - TipRanks
Has Salarius Pharmaceuticals Inc. Stock Ever Crashed Historical Volatility ReviewWeekly Watchlist of High Movers Released - metal.it
Why is Penny Stock Salarius Pharmaceuticals (SLRX) Up 182% Today? - TipRanks
Salarius Soars 60.57%—Is the Biotech Drama Just Beginning? - AInvest
Salarius Pharmaceuticals’ Recent Market Showdown - StocksToTrade
Salarius Pharmaceuticals stock soars after Nasdaq extends compliance deadline By Investing.com - Investing.com South Africa
Salarius Pharmaceuticals stock soars after Nasdaq extends compliance deadline - Investing.com
Decoding Salarius Pharmaceuticals’ Stock Movement - timothysykes.com
What MACD and RSI say about Salarius Pharmaceuticals Inc.Free Chart Driven High Reward Trading Setup - Newser
Salarius Pharmaceuticals Granted Nasdaq Compliance Extension - MSN
Salarius Pharmaceuticals granted Nasdaq extension to regain listing compliance - Investing.com
What are Salarius Pharmaceuticals Inc. company’s key revenue driversFree Stock Trend Scanner For 2025 - jammulinksnews.com
What are analysts’ price targets for Salarius Pharmaceuticals Inc. in the next 12 monthsBest Dividend Outlook For Consistent Profits - jammulinksnews.com
Quant Models Detect Momentum Reversal in Salarius Pharmaceuticals Inc.Verified Signal From Chart Patterns Detected - metal.it
Will Salarius Pharmaceuticals Inc. Stock Benefit from AI and Green Energy TrendsHigh Reward Investment Strategy for Beginners - Newser
What are the technical indicators suggesting about Salarius Pharmaceuticals Inc.Post Market Guidance For Smart Trading - jammulinksnews.com
When is Salarius Pharmaceuticals Inc. stock expected to show significant growthAchieve breakthrough gains with expert advice - jammulinksnews.com
What MACD and RSI say about Salarius Pharmaceuticals Inc. Free Intraday Trend Analysis for Fast Gains - Newser
Has Salarius Pharmaceuticals Inc. Stock Ever Crashed Historical Volatility Review 3-Year Equity Summary With Setup Insights - Newser
Does Salarius Pharmaceuticals Inc. stock perform well during market downturnsBoost your returns with professional guidance - jammulinksnews.com
What MACD and RSI say about Salarius Pharmaceuticals Inc. Reversal Pattern Insights with Entry Tips - Newser
What institutional investors are buying Salarius Pharmaceuticals Inc. stockInvest confidently with professional guidance - jammulinksnews.com
Why is Salarius Pharmaceuticals Inc. stock attracting strong analyst attentionOutstanding capital returns - jammulinksnews.com
What makes Salarius Pharmaceuticals Inc. stock price move sharplySuperior returns - jammulinksnews.com
Is Salarius Pharmaceuticals Inc. a growth stock or a value stockInvest in stocks with strong fundamentals - jammulinksnews.com
Should I hold or sell Salarius Pharmaceuticals Inc. stock in 2025Strongest growth potential - jammulinksnews.com
What is the dividend policy of Salarius Pharmaceuticals Inc. stockTransform your portfolio with high-yield stocks - jammulinksnews.com
Salarius Pharmaceuticals Inc Stock (SLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):